Back Pain News and Research

Latest Back Pain News and Research

Celgene to enforce REVLIMID intellectual property rights following receipt of Paragraph IV notification letter

Celgene Corporation today announced that information was posted on the FDA Web site indicating that an Abbreviated New Drug Application (ANDA) has been received by the Office of Generic Drugs (OGD) containing a "Paragraph IV" patent certification, for REVLIMID (lenalidomide) 25 mg capsules. Celgene has not yet received the Paragraph IV notification letter identifying the filer.

25 Aug 2010

Center For Diagnostic Imaging's new center in Avon offers interventional procedures for joint and back pain

Center for Diagnostic Imaging is pleased to announce the opening of an outpatient medical imaging and image-guided procedure center in Avon, Indiana. The new center allows CDI to better serve medical providers and patients in the western Indianapolis communities.

24 Aug 2010

Multidisciplinary approach to treat neck and back pain caused by accidents, injuries

Advanced Spine and Headache Center is pleased to announce their expansion into a multidisciplinary approach for the treatment of neck and back pain caused by an auto accident, sports injury, or work related injury. "Our main objective was to integrate physical medicine, chiropractic, physical and massage therapy, and family medicine under one location," said founder Dr. Alex Meltser.

23 Aug 2010

FDA approves Alexion's Rhode Island manufacturing facility as commercial supply source for Soliris

Alexion Pharmaceuticals, Inc. today announced that the US Food and Drug Administration (FDA) has approved Alexion's Rhode Island manufacturing facility (ARIMF) in Smithfield, Rhode Island as a second source of commercial supply for Soliris® (eculizumab).

23 Aug 2010

Prescription opioids can be gate way to illicit drug addiction: Study

Thirty-one of 75 patients hospitalized for opioid detoxification told University at Buffalo physicians they first got hooked on drugs legitimately prescribed for pain. Another 24 began with a friend's left-over prescription pills or pilfered from a parent's medicine cabinet. The remaining 20 patients said they got hooked on street drugs.

21 Aug 2010

Benvenue Medical enrolls first patient in landmark KAST trial

Benvenue Medical, Inc., a developer of minimally invasive solutions for spine repair, announced today that it has enrolled the first patient into the landmark KAST (Kiva® System as a Vertebral Augmentation Treatment - A Safety and Effectiveness Trial) study. The case was performed by Sean Tutton, MD FSIR, Associate Professor of Radiology and Surgery at the Medical College of Wisconsin in Milwaukee.

20 Aug 2010

FDA Advisory Committee votes in favor of expanding pain indications for Eli Lilly's Cymbalta

The U.S. Food and Drug Administration (FDA) Anesthetic and Life Support Drugs Advisory Committee voted 8-6 in favor of expanding the pain indications for Eli Lilly and Company's (NYSE: LLY) Cymbalta® (duloxetine HCl) to a broader pain population that will be further defined by the FDA, if approved.

20 Aug 2010

Celgene receives Japan's MHLW approval for REVLIMID in deletion 5q myelodysplastic syndrome patients

Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.

20 Aug 2010

Scientist explains way to determine right size for breast implants

"Miami likes glitz",explains Christopher Craft, M.D., which is why women here tend to get larger breast implants in comparison to the rest of the country. Craft attended Georgetown University, graduated from the University of Tennessee Medical School, and completed his plastic surgery training at the University of North Carolina at Chapel Hill. He's a trained general and plastic surgeon specializing in surgical procedures of the body, breasts and skin.

18 Aug 2010

Discovery can lead to new class of drugs for chronic pain treatment

Researchers have made a discovery that could lead to a brand new class of drugs to treat chronic pain caused by inflammatory conditions such as arthritis and back pain without numbing the whole body.

17 Aug 2010

Benvenue Medical commences treatment in U.S. with Blazer Vertebral Augmentation System

Benvenue Medical, Inc., a developer of minimally invasive solutions for spine repair, announced today that it has treated the first patient in the United States with the Blazer Vertebral Augmentation System - a new device for the treatment of vertebral compression fractures (VCFs). The case was performed by Francis Facchini, M.D., partner, VIR Chicago, at Adventist GlenOaks Hospital in Glendale Heights, Illinois.

13 Aug 2010

Tips to prevent back pain for frequent laptop users

The symptoms are familiar to any student who has ever spent a long night pounding out a paper on a laptop computer: an aching neck, throbbing head and tingling fingers.Because of the way the computers are designed, using a laptop almost inevitably leads to poor posture, said Kevin Carneiro, DO, a doctor in the Department of Physical Medicine and Rehabilitation at the University of North Carolina at Chapel Hill School of Medicine. Incorrect posture and computer overuse can cause debilitating physical problems, such as sore muscles or repetitive stress injuries. Typing can also cause carpal tunnel syndrome, an injury to the nerve that passes through the wrist.

12 Aug 2010

Today's Opinions and Editorials: Bringing down health care costs; More on the Medicare trustees report

Short of transforming the medical payment system, can we bring down health care costs by feasible fixes? Yes, by reducing the number of services that must be covered by every insurance policy and requiring higher copayments for patients using the highest cost providers (Robert Pozen, 8/10).

11 Aug 2010

Three-year efficacy data on STELARA for psoriasis presented at American Academy of Dermatology meeting

New study findings showed that a majority of patients with moderate to severe plaque psoriasis who had a previous response to STELARA® (ustekinumab) sustained a clinical response for up to three years with continued treatment regardless of their body weight. Investigators also presented findings from an integrated safety analysis that included data from one Phase 2 and three Phase 3 trials in which treatment with STELARA demonstrated a favorable benefit-risk profile for up to three years of treatment, consistent with previous analyses.

10 Aug 2010

Adversity-exposure may protect against psychiatric disturbances that occur with CBP: Study

A new study by researchers at the University at Buffalo and the University of California, Irvine, to be published in the September issue of the journal Pain, reveals that, for people with chronic back pain, having a little adversity in your life can be protective and beneficial.

6 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

DURECT second-quarter net loss decreases to $6.3 million

DURECT Corporation announced today financial results for the three months ended June 30, 2010. Total revenues were $7.3 million for the three months ended June 30, 2010 compared to $4.9 million for the three months ended June 30, 2009. Net loss for the three months ended June 30, 2010 was $6.3 million, compared to a net loss of $7.5 million for the same period in 2009.

5 Aug 2010

Painkiller combinations cost more but are less effective: Report

In a new article in the journal Australian Prescriber, there is a warning that combination painkillers cause more side effects and may not provide the relief promised. This comes from the National Prescribing Service (NPS), Australia's medicine review body.

1 Aug 2010

Ortho Kinematics: 23 patients enrolled in KineGraph VMA clinical study

Ortho Kinematics, a privately held spine diagnostics company focused on revolutionizing spine motion analysis, announced today that it has begun a multi-site clinical study of the KineGraph VMA™, and that the initial 23 patients have been enrolled. The study will help determine which types of patients are best evaluated with KineGraph VMA testing. The KineGraph VMA is designed to provide functional diagnostic information to spine surgeons to be used in conjunction with MRI and plain X-rays.

29 Jul 2010

Pivotal Phase 3 IMPACT study results of PROVENGE published in New England Journal of Medicine

Dendreon Corporation announced today the publication of data from the pivotal Phase 3 IMPACT study in the New England Journal of Medicine, showing that PROVENGE (sipuleucel-T) demonstrated a statistically significant improvement in overall survival compared to control in men with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer. The manuscript is published in the July 29, 2010 issue of the journal.

29 Jul 2010

Back Pain News and Research

Latest Back Pain News and Research

Celgene to enforce REVLIMID intellectual property rights following receipt of Paragraph IV notification letter

Center For Diagnostic Imaging's new center in Avon offers interventional procedures for joint and back pain

Multidisciplinary approach to treat neck and back pain caused by accidents, injuries

FDA approves Alexion's Rhode Island manufacturing facility as commercial supply source for Soliris

Prescription opioids can be gate way to illicit drug addiction: Study

Benvenue Medical enrolls first patient in landmark KAST trial

FDA Advisory Committee votes in favor of expanding pain indications for Eli Lilly's Cymbalta

Celgene receives Japan's MHLW approval for REVLIMID in deletion 5q myelodysplastic syndrome patients

Scientist explains way to determine right size for breast implants

Discovery can lead to new class of drugs for chronic pain treatment

Benvenue Medical commences treatment in U.S. with Blazer Vertebral Augmentation System

Tips to prevent back pain for frequent laptop users

Today's Opinions and Editorials: Bringing down health care costs; More on the Medicare trustees report

Three-year efficacy data on STELARA for psoriasis presented at American Academy of Dermatology meeting

Adversity-exposure may protect against psychiatric disturbances that occur with CBP: Study

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

DURECT second-quarter net loss decreases to $6.3 million

Painkiller combinations cost more but are less effective: Report

Ortho Kinematics: 23 patients enrolled in KineGraph VMA clinical study

Pivotal Phase 3 IMPACT study results of PROVENGE published in New England Journal of Medicine

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Back Pain News and Research

Latest Back Pain News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in